US court upholds Evista patents through 2014, blocking Teva generic
25 September 2009
Nancy Faigen
A US federal judge has upheld
Lilly's method-of-use patents for its osteoporosis drug Evista (raloxifene) through to March 2014, blocking an attempt by
Teva Pharmaceutical Industries to sell a generic version. The product has annual US sales of around $650 million. Teva said it plans to appeal the...
Please Login to read the full article.
25 September 2009
Nancy Faigen
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Court rulings in gene patent, stem cell cases provide new hope for biopharma
- Watson beatsTeva on appeals overgeneric Seasonique: sued by Novartis over Exelon
- Supreme Court upholds 'clear and convincing' patent standard, rules against Microsoft
- US Capitol Capsule: Supreme Court to weigh generic drug liability, patent burden-of-proof standards
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
